Samsung Bioepis collaborates to make inroads into original drugs

05:14 EDT 21 Aug 2017 | Pharmafile

Thus far, Samsung Bioepis has made its name by being a thorn in the side of the producers of original drugs. It has become a world leader in producing biosimilars, already gaining approval for a biosimilar to J&J’s Remicade whilst having decisions pending on several others. Now, it has formed a partnership with Takeda to begin the search for its own product to launch onto the market.

read more

Original Article: Samsung Bioepis collaborates to make inroads into original drugs


More From BioPortfolio on "Samsung Bioepis collaborates to make inroads into original drugs"

Quick Search


Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...